Previous Page  7 / 28 Next Page
Information
Show Menu
Previous Page 7 / 28 Next Page
Page Background

Page 41

Notes:

conferenceseries

.com

Volume 08

Journal of Alzheimers Disease & Parkinsonism

Alzheimer's Congress 2018

May 30-31, 2018

May 30-31, 2018 Osaka, Japan

10

th

World Congress on

Alzheimer's Disease & Dementia

Rosmarinic acid and curcumin-loaded polyacrylamide-cardiolipin-poly(lactide-co-glycolide)

nanoparticles with conjugated 83-14 monoclonal antibody to protect β-amyloid-insulted neurons

Yung-Chih Kuo and He-Cheng Tsai

National Chung Cheng University, Taiwan

P

olymeric nanoparticles (NPs) combined with lipids can have profound effects on treatment efficacy in patients with

neurological disorders such as Alzheimer’s Disease (AD). We developed polyacrylamide (PAAM)-cardiolipin (CL)-

poly(lactide-co-glycolide) (PLGA) NPs grafted with surface 83-14Monoclonal Antibody (MAb) to carry Rosmarinic Acid (RA)

and Curcumin (CUR). This drug delivery system was used to cross the Blood-Brain Barrier (BBB) and enhance the viability of

SK-N-MC cells insulted with β-Amyloid (Aβ) deposits. Experimental evidence revealed that an increase in the concentration

of 83-14 MAb enhanced the permeability coefficient of RA and CUR using the nanocarriers. The levels of phosphorylated p38

and phosphorylated τ-protein at serine 202 in degenerated SK-N-MC cells were in the order: Aβ>(Aβ+RA-CUR)>(Aβ+83-14

MAb-RA-CUR-PAAM-PLGA NPs)>(Aβ+83-14 MAb-RA-CUR-PAAM-CL-PLGA NPs)≈control. The viability of SK-N-MC

cells reduced with time and CL in 83-14 MAb-RA-CUR-PAAM-CL-PLGA NPs advantaged Aβ-targeted delivery of RA-CUR.

These results evidenced that the current 83-14 MAb-RA-CUR-PAAM-CL-PLGA NPs can be a promising pharmacotherapy to

permeate the BBB and reduce the fibrillar Aβ-induced neurotoxicity.

Biography

Yung-Chih Kuo is a Professor at National Chung Cheng University, Taiwan. His research interests are focused on biomaterials, nanomedicine, tissue engineering,

blood-brain barrier, cancer therapy, nerve regeneration, spinal cord injury and stroke treatment and Alzheimer’s and Parkinson’s disease therapy. He has authored

over 140 SCI journal papers. He is a Fellow of Royal Society of Chemistry, UK and an Honor Member of Phi Tau Phi Society. He has also won Prof. Yen-Ping Shih

Award in 2017; Best Paper Award in 2016 and 2008; Prof. Tsai-Teh Lai Award in 2015; Special and Talented Scholar Award in 2013 and Outstanding Research

Award in 2013.

chmyck@ccu.edu.tw

Yung-Chih Kuo

et.al.

, J Alzheimers Dis Parkinsonism 2018, Volume 8

DOI: 10.4172/2161-0460-C4-046